Patents by Inventor Matthew Cullen
Matthew Cullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260284318Abstract: A mixing syringe assembly includes a barrel body and a sealing device. The barrel body includes a track defining a first longitudinal path, a second longitudinal path, and a rotational path. The first longitudinal path and the second longitudinal path are rotationally offset from one another by the rotational path. The sealing device is positioned in a dividing position between within the rotational path, the sealing device dividing the barrel body into a first constituent material section and a second constituent material section. The sealing device is rotatable within the rotational path allowing the sealing device to enter the second longitudinal path and be advanced along the second longitudinal path. The sealing device is operable to adjust from a sealing configuration to a non-sealing configuration to allow for first constituent material from the first constituent material section to move into the second constituent material section holding second constituent material.Type: ApplicationFiled: April 26, 2024Publication date: September 24, 2026Applicant: CLEARSTREAM TECHNOLOGIES LIMITEDInventor: Matthew Cullen
-
Publication number: 20260284317Abstract: A mixing syringe assembly for mixing two constituent materials includes a barrel body, and a barrel connector. The barrel body has a first portion and a second portion. The barrel connector connects the first portion to the second portion includes a twisting seal having a plurality of flaps. The twisting seal is operable to be actuated from a closed configuration wherein the twisting seal seals the first portion from the second portion and an open configuration in which the plurality of flaps twist apart to provide an opening between the first portion and the second portion.Type: ApplicationFiled: April 26, 2024Publication date: September 24, 2026Applicant: CLEARSTREAM TECHNOLOGIES LIMITEDInventor: Matthew Cullen
-
Publication number: 20260241105Abstract: An injection needle assembly includes a hub having a first input port and a second input port, and an outer hub portion rotatably coupled about an inner hub portion having a cam. An elongate hollow stylet extends distally from the hub and includes a proximal end at the hub and distal end spaced a distance from the proximal end. A cannula receives the elongate hollow stylet such that the elongate hollow stylet and the cannula define an inner lumen and an outer lumen separate from the inner lumen, the cannula further including a proximal end and a distal end spaced a distance from the proximal end. The elongate hollow stylet is coupled to the hub such that the proximal end of the elongate hollow stylet engages with the cam and rotation of the outer hub portion translates the elongate hollow stylet between an extended position and a retracted position.Type: ApplicationFiled: March 8, 2024Publication date: August 20, 2026Applicant: Clearstream Technologies LimitedInventors: Matthew CULLEN, Tyler LENT, William E. PARMENTIER
-
Publication number: 20260224801Abstract: In one embodiment, a mixing syringe assembly for mixing two constituent materials includes a barrel body, a plunger, a sealing device, and one or more mixing masses. The plunger is slidably positioned within the barrel body. The sealing device divides the barrel body into a first constituent material section and a second constituent material section. The one or more mixing masses are positioned within one of the first constituent material section and the second constituent material section. The sealing device is operable to adjust from a sealing configuration to a non-sealing configuration to allow for a first constituent material from the first constituent material section to move into the second constituent material section upon movement of the plunger along the barrel body and be mixed therein with the one or more mixing masses.Type: ApplicationFiled: March 8, 2024Publication date: August 6, 2026Applicant: CLEARSTREAM TECHNOLOGIES LIMITEDInventors: Ruben Ramirez, Charles D. Shermer, Victor Bell, Jordan Addison, Matthew Cullen
-
Patent number: 12319698Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: GrantFiled: November 18, 2022Date of Patent: June 3, 2025Assignee: Kineta, Inc.Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
-
Publication number: 20250108167Abstract: A system for mixing and delivering content is disclosed. The system includes an applicator, a needle assembly, and a micro seal. The applicator includes two component chambers separate from one another, each component chamber including at least one output port on a distal end thereof and an applicator hub disposed on a distal end of the applicator adjacent to the at least one output port of each component chamber. The needle assembly includes an elongate hollow stylet having a plurality of lumens therein and a needle hub having an interior cannula fluidly coupled to the elongate hollow stylet. The micro seal is disposed within the applicator hub. The micro seal is configured to receive the interior cannula of the needle hub to establish a fluid coupling between each of the two component chambers with a respective one of the lumens within the elongate hollow stylet.Type: ApplicationFiled: September 27, 2024Publication date: April 3, 2025Applicant: CLEARSTREAM TECHNOLOGIES LIMITEDInventors: Matthew Cullen, Victor Bell
-
Patent number: 12180189Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.Type: GrantFiled: November 21, 2019Date of Patent: December 31, 2024Assignee: Kineta, Inc.Inventors: Megan Foley, Bradley Tait, Matthew Cullen
-
Publication number: 20240335611Abstract: A component delivery system is disclosed. The component delivery system includes an applicator including two chambers separate from one another, each chamber including at least one output port on a distal end thereof for receiving corresponding pistons. The component delivery system further includes a two-piece alignment fixture removably couplable to the applicator and a two-piece piston insert removably couplable to the pistons, the two-piece piston insert engagable with the two-piece alignment fixture to prevent removal of the pistons from the two chambers.Type: ApplicationFiled: June 20, 2024Publication date: October 10, 2024Applicant: CLEARSTREAM TECHNOLOGIES LIMITEDInventors: Matthew Cullen, Dylan Beyhl, Jordan P. Addison, Victor Bell
-
Patent number: 11958873Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: GrantFiled: December 17, 2021Date of Patent: April 16, 2024Assignee: Kineta, Inc.Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
-
Publication number: 20240116894Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: ApplicationFiled: July 12, 2023Publication date: April 11, 2024Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
-
Patent number: 11746098Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: GrantFiled: December 23, 2020Date of Patent: September 5, 2023Assignee: Proteostasis Therapeutics, Inc.Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
-
Publication number: 20230242557Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: ApplicationFiled: December 17, 2021Publication date: August 3, 2023Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
-
Publication number: 20230183256Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: ApplicationFiled: November 18, 2022Publication date: June 15, 2023Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
-
Patent number: 11560385Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: GrantFiled: December 23, 2020Date of Patent: January 24, 2023Assignee: Proteostasis Therapeutics, Inc.Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
-
Publication number: 20220298181Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: ApplicationFiled: December 17, 2021Publication date: September 22, 2022Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
-
Patent number: 11242361Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: GrantFiled: June 15, 2020Date of Patent: February 8, 2022Assignee: Proteostasis Therapeutics, Inc.Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
-
Publication number: 20210188802Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: ApplicationFiled: December 23, 2020Publication date: June 24, 2021Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
-
Publication number: 20210115057Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: ApplicationFiled: December 23, 2020Publication date: April 22, 2021Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
-
Patent number: 10899751Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.Type: GrantFiled: June 21, 2017Date of Patent: January 26, 2021Assignee: Proteostasis Therapeutics, Inc.Inventors: Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
-
Publication number: 20200308198Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.Type: ApplicationFiled: June 15, 2020Publication date: October 1, 2020Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait